Response to comment on “New therapeutic agents in diabetic nephropathy”
نویسندگان
چکیده
منابع مشابه
Response to comment on “New therapeutic agents in diabetic nephropathy”
Correspondence to Cheol Whee Park, M.D. Division of Nephrology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea Tel: +82-2-2258-6038 Fax: +82-2-599-3589 E-mail: [email protected] Thank you for your interest in the article entitled “New therapeutic agents in diabetic nephropathy”...
متن کاملComment on “New therapeutic agents in diabetic nephropathy”
Correspondence to Alain Gay, M.D. Bayer AG, Mullerstrasse, 178, Berlin 13342, Germany Tel: +49-3046-8192003 Fax: +49-3046-8992003 E-mail: [email protected] We have read with great interest the article “New therapeutic agents in diabetic nephropathy” Korean J Intern Med 2017;32:11-25 by Yaeni Kim and Cheol Whee Park [1]. The authors stated that ‘the Proteomic prediction and Renin angiotensin a...
متن کاملNew therapeutic agents in diabetic nephropathy
Studies investigating diabetic nephropathy (DN) have mostly focused on interpreting the pathologic molecular mechanisms of DN, which may provide valuable tools for early diagnosis and prevention of disease onset and progression. Currently, there are few therapeutic drugs for DN, which mainly consist of antihypertensive and antiproteinuric measures that arise from strict renin-angiotensin-aldost...
متن کاملImpact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients
Metabolic syndrome and its pathological sequel, type 2 diabetes are considered as important global health problems. Metformin is the most common drug prescribed for patients with this disorder. Consequently, understanding the genetic pathways involved in pharmacokinetics and pharmacodynamics of this drug can have a considerable effect on the personalized treatment of type 2 diabetes. In this st...
متن کاملInflammation and Oxidative Stress in Diabetic Nephropathy: New Insights on Its Inhibition as New Therapeutic Targets
Diabetes and insulin resistance can greatly increase microvascular complications of diabetes including diabetic nephropathy (DN). Hyperglycemic control in diabetes is key to preventing the development and progression of DN. However, it is clinically very difficult to achieve normal glucose control in individual diabetic patients. Many factors are known to contribute to the development of DN. Th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Korean Journal of Internal Medicine
سال: 2017
ISSN: 1226-3303,2005-6648
DOI: 10.3904/kjim.2017.154